Hostname: page-component-77c89778f8-gvh9x Total loading time: 0 Render date: 2024-07-17T06:26:13.112Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of a Moderate Blood Exchange with Fluosol-Da 20% on the Disposition of Digoxin in the Dog

Published online by Cambridge University Press:  26 February 2011

John F. Hoke  and
William R. Ravis
John F. Hoke
Affiliation:
Auburn University, Dept. of Pharmacal Sciences, School of Pharmacy, Auburn, Alabama 36849
William R. Ravis
Affiliation:
Auburn University, Dept. of Pharmacal Sciences, School of Pharmacy, Auburn, Alabama 36849
Get access

Abstract

The effect of a perfluorochemical blood substitute (Fluosol-DA 20%) on the disposition kinetics of digoxin in the dog was studied. An intravenous dose of digoxin was administered at either 0.25 or 24 hours following a 30% blood exchange with the dog's own blood (SHAM group) or Fluosol-DA (treatment group). A significant change in the initial volume of distribution and mean residence time in the serum was noted when digoxin was administered 0.25 hours after the Fluosol-DA blood exchange. This volume of distribution change was not observed when digoxin was administered 24 hours after the Fluosol-DA blood exchange. No change in the t1/2, total body clearance, or volume of distribution at steady-state was observed in any of the treatments. No change in the partitioning of digoxin in the blood was noted following Fluosol-DA administration.

Type
Research Article
Information
MRS Online Proceedings Library (OPL) , Volume 110: Symposium M – Biomedical Materials and Devices , 1987 , 141
Copyright
Copyright © Materials Research Society 1988

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Naito, R. and Yokoyama, K., Perfluorochemical Blood Substitutes, The Green Cross Corp. (Technical Information Ser. No. 5, 1981), p. 17, 32, 36, 65, 89.Google Scholar
2. Fujita, T., Suzuki, C., and Ogawa, R., in Advances in Blood Substitute Research, edited by Bolin, R. B., Geyer, R. P., and Nemo, G.J. (Prog. Clin. Biol. Res. 122, New York, 1983) pp. 265–272.Google Scholar
3. Hodges, G.R., Reed, J.S., Hignite, C.E., and Snodgrass, W.R., in Advances in Blood Substitute Research, edited by Bolin, R. B., Geyer, R. P., and Nemo, G.J. (Prog. Clin. Biol. Res. 122, New York, 1983) (Abstract), pp. 430–431.Google Scholar
4. Kemner, J.M., Snodgrass, W.R., Worley, S.E., Hodges, G.R., Clark, G.M. and Hignite, C.E., J. Lab. Clin. Med. 104, 433 (1984).Google Scholar
5. Kemner, J.M., Snodgrass, W.R., Worley, S.E., Hodges, G.R., Melethil, S., Hignite, C.E. and Tschanz, C., Res. Commun. Chem. Pathol. Pharmacol. 46, 381 (1984).Google Scholar
6. Shrewsbury, R.P., White, S.G., Pollack, G.M. and Wargin, W.A., J. Pharm. Pharmacol. 38, 883 (1986).Google Scholar
7. Shrewsbury, R.P., J. Pharm. Pharmacol., 38, 647 (1986).Google Scholar
8. Metzler, C.M., Elfring, G.L. and McEwen, A.J., Biometrics 30, 562 (1974).CrossRefGoogle Scholar
9. Bolton, S., Pharmaceutical Statistics - Practical and Clinical Apolications, Vol.25 (Marcel Dekker, Inc., New York, 1984), pp. 218–252.Google Scholar
10. Reuning, R.H. and Geraets, D.R., in Applied Pharmacokinetics: Principles of Theraoeutic Drug Monitoring, edited by Evans, W.E., Schentage, J.J. and Jusko, W.J. (Applied Therapeutics, Inc., San Francisco, CA, 1986) pp. 578–584.Google Scholar